Bone Marrow Dosimetry in Radioiodine (I-131) Treatment
PDF
Cite
Share
Request
Review
VOLUME: 11 ISSUE: 1
P: 15 - 20
March 2025

Bone Marrow Dosimetry in Radioiodine (I-131) Treatment

Nucl Med Semin 2025;11(1):15-20
No information available.
No information available
Received Date: 14.01.2025
Accepted Date: 10.03.2025
Online Date: 18.03.2025
Publish Date: 18.03.2025
PDF
Cite
Share
Request

Abstract

In radioiodine therapies, the most radiosensitive tissue in the body is the red bone marrow. The maximum iodine-131 activity is calculated through dosimetry to ensure that the blood-representing the dose-limiting organ, the bone marrow-receives a dose below 2 Gy during treatment. Dosimetry involves calculations based on measuring blood samples collected from the patient after administering approximately 74 MBq (2 mCi) of radioiodine, using a gamma counter.

Keywords:
Radioiodine treatment, bone marrow dosimetry, dosimetry on I-131 treatment